Zevra Therapeutics to Present at the Citizens Life Sciences Conference
Rhea-AI Summary
Zevra Therapeutics (Nasdaq: ZVRA) announced that its executive leadership will present at the Citizens Life Sciences Conference in Miami Beach on March 11, 2026 at 9:00 a.m. ET.
Management will hold one-on-one meetings with registered attendees and a live webcast will be available via the Events & Presentations page on Zevra's investor website.
Positive
- None.
Negative
- None.
News Market Reaction – ZVRA
In the Feb 25 session, ZVRA declined 0.45%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 04 | Clinical data update | Positive | -2.4% | Positive real-world MIPLYFFA data in NPC presented at WORLDSymposium. |
| Feb 02 | Corporate event | Positive | +4.0% | Nasdaq opening bell ceremony featuring CEO remarks and live stream. |
| Jan 26 | Conference preview | Positive | +0.6% | Planned multiple MIPLYFFA analyses and presentations at WORLDSymposium. |
| Jan 08 | Conference appearance | Positive | +1.8% | Management presentation and 1x1 meetings at J.P. Morgan Healthcare Conference. |
| Dec 29 | Commercial agreement | Positive | -0.6% | Distribution deal with Uniphar to broaden access to MIPLYFFA outside Europe. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive news has more often led to modest gains, with occasional negative divergences.
Over the past few months, Zevra has focused on MIPLYFFA® for Niemann-Pick disease type C, including new real-world data and multiple WORLDSymposium™ presentations. Corporate visibility events such as conference appearances and the Nasdaq opening bell on Feb 9, 2026 have also featured prominently. A December 2025 distribution agreement aimed to broaden MIPLYFFA access outside Europe. Compared with those milestones, today’s Citizens Life Sciences Conference appearance continues the pattern of investor-relations and scientific-outreach activity.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CELEBRATION, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that members of Zevra’s executive leadership team will present at the Citizens Life Sciences Conference in Miami Beach, FL on Wednesday, March 11, 2026, at 9:00 a.m. ET.
Additionally, management will be available for one-on-one meetings with registered conference attendees. A link to the live webcast will be accessible on the “Events & Presentations” page in the Investor Relations section of Zevra’s website at investors.zevra.com.
About Zevra Therapeutics, Inc.
Zevra Therapeutics, Inc. is a purpose-driven, commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases. The company’s commercialization of its lead product, marketed in the U.S. for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disorder, provides a strong corporate foundation and validates its ability to advance therapies. In addition, the company is broadening access through geographic expansion opportunities and has a pipeline of rare disease programs. Zevra is a patient-centric organization guided by our values of accountability, integrity, innovation and courage, with the goal of creating long-term value for patients, partners, and shareholders.
For more information, please visit www.zevra.com or follow us on X and LinkedIn.
Caution Concerning Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts. Forward-looking statements are based on information currently available to Zevra and its current plans or expectations. They are subject to several known and unknown uncertainties, risks, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the "Risk Factors" section of Zevra’s Annual Report on Form 10-K for the year ended December 31, 2024, filed on March 12, 2025, Quarterly Report on Form 10-Q for the three and nine months ended September 30, 2025, filed on November 5, 2025, as well as Zevra’s other filings with the Securities and Exchange Commission. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we cannot assure that such expectations will prove correct. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release.
Investor Contact
Nichol Ochsner
+1 (732) 754-2545
nochsner@zevra.com
Media Contact
Julie Downs
+1 (508) 246-3230
jdowns@zevra.com
